Trevi Therapeutics, Inc.
TRVIHeld by 3 specialist biotech funds
High ConvergenceHigh short interest · No specialist buying3 funds opened new positions. Short interest: 11.2% of float.
Held by 3 specialist biotech funds
High ConvergenceHigh short interest · No specialist buying3 funds opened new positions. Short interest: 11.2% of float.
Trevi Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of Haduvio to treat serious neurologically mediated conditions. The company is developing Haduvio, an oral extended-release formulation of nalbuphine, which is in phase IIb/III clinical trial for the treatment of chronic pruritus, chronic cough in patients with idiopathic pulmonary fibrosis. It has a license agreement with Endo Pharmaceuticals Inc. to develop and commercialize products incorporating nalbuphine hydrochloride in any formulation. The company was incorporated in 2011 and is headquartered in New Haven, Connecticut.
Be first to know when this name moves
Fund buys and exits, insider activity, and catalyst alerts across 800+ biotechs — free Monday brief.